Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update

G. Holleran, F. Scaldaferri, G. Ianiro, L. Lopetuso, D. Mc Namara, M. C. Mele, A. Gasbarrini, G. Cammarota

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Fecal microbiota transplantation (FMT) is the transplantation of microbial gut contents from a healthy individual into the gastrointestinal tract of a person with a disease, with a view to increasing the recipient's gut microbial diversity and bacterial richness and restoring microbial homeostasis. FMT has been proven to be a safe and effective treatment for Clostridium difficile infection (CDI) and it is now a recommended treatment for recurrent or refractory infection. FMT is not currently recommended for use outside of CDI due to concerns regarding outcome and safety; however, several case series and randomized controlled trials have described its use in a research environment for a few gastrointestinal conditions related to intestinal dysbiosis including ulcerative colitis (UC), Crohn's disease (CD) and irritable bowel syndrome (IBS). The most successful reports of the clinical efficacy of FMT in gastrointestinal conditions outside of CDI have been in treating UC. We summarize the current literature regarding the use of FMT in UC, including methodology, clinical efficacy and safety concerns, and identify pitfalls and areas for future development. We also describe the available evidence to date on the use of FMT in CD, IBS and other conditions related to intestinal dysbiosis.

Original languageEnglish
Pages (from-to)123-136
Number of pages14
JournalDrugs of Today
Volume54
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Clostridium Infections
Clostridium difficile
Ulcerative Colitis
Dysbiosis
Irritable Bowel Syndrome
Crohn Disease
Therapeutics
Safety
Gastrointestinal Tract
Fecal Microbiota Transplantation
Homeostasis
Randomized Controlled Trials
Transplantation
Infection
Research

Keywords

  • Crohn's disease
  • Fecal microbiota transplantation
  • Intestinal dysbiosis
  • Irritable bowel syndrome
  • Ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{ce4842ba9a3448c08f19e1a3256ba7f3,
title = "Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update",
abstract = "Fecal microbiota transplantation (FMT) is the transplantation of microbial gut contents from a healthy individual into the gastrointestinal tract of a person with a disease, with a view to increasing the recipient's gut microbial diversity and bacterial richness and restoring microbial homeostasis. FMT has been proven to be a safe and effective treatment for Clostridium difficile infection (CDI) and it is now a recommended treatment for recurrent or refractory infection. FMT is not currently recommended for use outside of CDI due to concerns regarding outcome and safety; however, several case series and randomized controlled trials have described its use in a research environment for a few gastrointestinal conditions related to intestinal dysbiosis including ulcerative colitis (UC), Crohn's disease (CD) and irritable bowel syndrome (IBS). The most successful reports of the clinical efficacy of FMT in gastrointestinal conditions outside of CDI have been in treating UC. We summarize the current literature regarding the use of FMT in UC, including methodology, clinical efficacy and safety concerns, and identify pitfalls and areas for future development. We also describe the available evidence to date on the use of FMT in CD, IBS and other conditions related to intestinal dysbiosis.",
keywords = "Crohn's disease, Fecal microbiota transplantation, Intestinal dysbiosis, Irritable bowel syndrome, Ulcerative colitis",
author = "G. Holleran and F. Scaldaferri and G. Ianiro and L. Lopetuso and {Mc Namara}, D. and Mele, {M. C.} and A. Gasbarrini and G. Cammarota",
year = "2018",
month = "2",
day = "1",
doi = "10.1358/dot.2018.54.2.2760765",
language = "English",
volume = "54",
pages = "123--136",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection

T2 - An update

AU - Holleran, G.

AU - Scaldaferri, F.

AU - Ianiro, G.

AU - Lopetuso, L.

AU - Mc Namara, D.

AU - Mele, M. C.

AU - Gasbarrini, A.

AU - Cammarota, G.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Fecal microbiota transplantation (FMT) is the transplantation of microbial gut contents from a healthy individual into the gastrointestinal tract of a person with a disease, with a view to increasing the recipient's gut microbial diversity and bacterial richness and restoring microbial homeostasis. FMT has been proven to be a safe and effective treatment for Clostridium difficile infection (CDI) and it is now a recommended treatment for recurrent or refractory infection. FMT is not currently recommended for use outside of CDI due to concerns regarding outcome and safety; however, several case series and randomized controlled trials have described its use in a research environment for a few gastrointestinal conditions related to intestinal dysbiosis including ulcerative colitis (UC), Crohn's disease (CD) and irritable bowel syndrome (IBS). The most successful reports of the clinical efficacy of FMT in gastrointestinal conditions outside of CDI have been in treating UC. We summarize the current literature regarding the use of FMT in UC, including methodology, clinical efficacy and safety concerns, and identify pitfalls and areas for future development. We also describe the available evidence to date on the use of FMT in CD, IBS and other conditions related to intestinal dysbiosis.

AB - Fecal microbiota transplantation (FMT) is the transplantation of microbial gut contents from a healthy individual into the gastrointestinal tract of a person with a disease, with a view to increasing the recipient's gut microbial diversity and bacterial richness and restoring microbial homeostasis. FMT has been proven to be a safe and effective treatment for Clostridium difficile infection (CDI) and it is now a recommended treatment for recurrent or refractory infection. FMT is not currently recommended for use outside of CDI due to concerns regarding outcome and safety; however, several case series and randomized controlled trials have described its use in a research environment for a few gastrointestinal conditions related to intestinal dysbiosis including ulcerative colitis (UC), Crohn's disease (CD) and irritable bowel syndrome (IBS). The most successful reports of the clinical efficacy of FMT in gastrointestinal conditions outside of CDI have been in treating UC. We summarize the current literature regarding the use of FMT in UC, including methodology, clinical efficacy and safety concerns, and identify pitfalls and areas for future development. We also describe the available evidence to date on the use of FMT in CD, IBS and other conditions related to intestinal dysbiosis.

KW - Crohn's disease

KW - Fecal microbiota transplantation

KW - Intestinal dysbiosis

KW - Irritable bowel syndrome

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85048105648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048105648&partnerID=8YFLogxK

U2 - 10.1358/dot.2018.54.2.2760765

DO - 10.1358/dot.2018.54.2.2760765

M3 - Review article

C2 - 29637938

AN - SCOPUS:85048105648

VL - 54

SP - 123

EP - 136

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 2

ER -